Literature DB >> 11600387

Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

N Lounis1, C Truffot-Pernot, A Bentoucha, J Robert, B Ji, J Grosset.   

Abstract

Mice were infected intravenously with 3.5 x 10(7) CFU of Mycobacterium xenopi and treated with various clarithromycin-containing regimens or left untreated for 4 weeks. All nine of the clarithromycin-containing regimens reduced the CFU counts to the levels below the pretreatment values, indicating that these regimens had a bactericidal effect on M. xenopi in mice. The rifampin-isoniazid-ethambutol regimen was significantly less bactericidal than clarithromycin alone or clarithromycin-containing combined regimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600387      PMCID: PMC90813          DOI: 10.1128/AAC.45.11.3229-3230.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1997-08       Impact factor: 21.405

2.  Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi.

Authors:  B Roche; S Rozenberg; E Cambau; N Desplaces; E Dion; G Dubourg; A C Koeger; H Robin; H Vergeron; P Bourgeois
Journal:  Rev Rhum Engl Ed       Date:  1997-01

3.  Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin, and sparfloxacin.

Authors:  H Schmitt; N Schnitzler; J Riehl; G Adam; H G Sieberth; G Haase
Journal:  Clin Infect Dis       Date:  1999-07       Impact factor: 9.079

4.  Mycobacterium xenopi infection in patients with human immunodeficiency virus infection.

Authors:  P el-Helou; A Rachlis; I Fong; S Walmsley; A Phillips; I Salit; A E Simor
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

5.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Clarithromycin is inactive against Mycobacterium tuberculosis.

Authors:  C Truffot-Pernot; N Lounis; J H Grosset; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

  7 in total
  5 in total

1.  Pulmonary disease caused by Mycobacterium xenopi: the first case in Korea.

Authors:  Hye Yun Park; Won-Jung Koh; O Jung Kwon; Nam Yong Lee; Young Mog Shim; Young Kil Park; Gill Han Bai; Ho-Suk Mun; Bum-Joon Kim
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

2.  Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

3.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

4.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

5.  A case of pulmonary Mycobacterium heckeshornense infection in a healthy Japanese man.

Authors:  Eriko Iitoh; Masaki Tominaga; Masaki Okamoto; Yuki Sakazaki; Masayuki Nakamura; Takashi Kinoshita; Tomotaka Kawayama; Tomoaki Hoshino
Journal:  Respir Med Case Rep       Date:  2020-05-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.